NCT04856371 - Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer | Biotech Hunter

Enrollment

228

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

December 31, 2022

Conditions

Advanced Breast Cancer

Interventions

DRUG

CYH33

Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.

DRUG

Fulvestrant

Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1, 15 on Cycle 1 (28-day cycle) and Day 1 at each 28-day cycle thereafter.

DRUG

Letrozole

Participants will receive oral letrozole once daily continuous on Day 1-28 of each cycle.

DRUG

Palbociclib

Participants will receive palbociclib once daily continuous on Day 1-21 of each 28-day cycle.